ORTX News and Press, Orchard Therapeutics plc From 12/17/20

Today, we take a look at Orchard Therapeutics, a developmental concern from across the pond that has discernible potential catalysts on the horizon. With a couple of drug candidates in late-stage development, this is an intriguing name in the gene therapy space. Orchard will be ad...

Orchard Therapeutics (ORTX) has reported initial data from an ongoing proof-of-concept trial evaluating OTL-201, an autologous hematopoietic stem cell gene therapy candidate, for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA, or Sanfilippo syndrome type A), an inhe...

BOSTON and LONDON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, yesterday reported initial data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-201, an investigational ex vivo ...

The largest pharmaceutical companies in the world are restructuring.  Biopharma represents a far more valuable future than growth-dilutive consumer health revenues. GSK cleared room for next generation oncology cellular medicines by selling their prior portfolio to Novartis. ...

BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph.D. will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtu...

The FDA has signed-off Orchard Therapeutics' ([[ORTX]] +3.2%) Investigational New Drug application for OTL-200, an autologous, hematopoietic stem cell, lentiviral vector-based gene therapy in development for the treatment of metachromatic leukodystrophy ((MLD)). The company also has applied f...

BOSTON and LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for OTL-200, an autologous, he...

Developing drugs to treat or cure rare diseases can be a lucrative line of business, as Orchard Therapeutics (NASDAQ: ORTX) and Alexion Pharmaceuticals (NASDAQ: ALXN) know. While it might seem highly limiting to target conditions that only affect a handful of patients worldw...

First look at preclinical data in f rontotemporal dementia with progranulin mutations ( GRN- FTD) and new amyotrophic lateral sclerosis (ALS) program NOD2 mutation revealed as Crohn’s disease (CD) genetic target,...

BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020 at 11:15 AM ET. A live webcast o...